{"id":542769,"date":"2021-05-11T18:42:01","date_gmt":"2021-05-11T18:42:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542769"},"modified":"2021-05-11T18:42:01","modified_gmt":"2021-05-11T18:42:01","slug":"tendinitis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-seikagaku-corporation-metriopharm-mimedx-zhejiang-xingyue-biotechnology-co-ltd-r3-stem-cell-dobecure","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/tendinitis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-seikagaku-corporation-metriopharm-mimedx-zhejiang-xingyue-biotechnology-co-ltd-r3-stem-cell-dobecure_542769.html","title":{"rendered":"Tendinitis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Seikagaku Corporation, MetrioPharm, MiMedx, Zhejiang Xingyue Biotechnology Co., Ltd., R3 Stem Cell, Dobecure"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1620728763.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Tendinitis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Seikagaku Corporation, MetrioPharm, MiMedx, Zhejiang Xingyue Biotechnology Co., Ltd., R3 Stem Cell, Dobecure\" src=\"https:\/\/www.abnewswire.com\/uploads\/1620728763.jpeg\" alt=\"Tendinitis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Seikagaku Corporation, MetrioPharm, MiMedx, Zhejiang Xingyue Biotechnology Co., Ltd., R3 Stem Cell, Dobecure\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Tendinitis Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Tendinitis<\/strong> is an inflammation of a tendon, a group of sturdy fibers that connects a muscle to the nearby bone. Another commonly used term for tendinitis is tendinopathy. Tendinitis is generally caused by injury, trauma, or overuse of a joint. Tendinitis may be referred to by a more specific description depending on the location where it occurs, such as Achilles tendinitis or tennis elbow. The elbows, heel, shoulder and wrist are common locations for tendinitis. Tendinitis is treated with rest along with medications to relieve pain and reduce inflammation. Physical therapy can be helpful to improve muscle strength and enhance healing. In some cases, surgery will need to be performed to repair tendon damage.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,&nbsp;<strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/tendinitis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Tendinitis Pipeline<\/a> Insight, 2021,&rdquo;<\/strong>&nbsp;report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Tendinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Tendinitis Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Seikagaku Corporation<\/li>\n<li>MetrioPharm<\/li>\n<li>MiMedx<\/li>\n<li>Zhejiang Xingyue Biotechnology Co., Ltd.<\/li>\n<li>R3 Stem Cell<\/li>\n<li>Dobecure<\/li>\n<li>Causeway Therapeutics<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/tendinitis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/tendinitis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Tendinitis report covers around 4+ products under different phases of clinical development like:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/tendinitis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Tendinitis Therapies<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>SI-613<\/li>\n<li>MP1032<\/li>\n<li>dHACM<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/tendinitis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/tendinitis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Current <\/strong><strong>Tendinitis Treatment<\/strong><strong> Scenario and <\/strong><strong>Tendinitis Emerging Therapies<\/strong><strong>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Tendinitis drugs?<\/li>\n<li>How many Tendinitis drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tendinitis?<\/li>\n<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Tendinitis therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Tendinitis and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/tendinitis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/tendinitis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Tendinitis: Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Tendinitis &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">Tendinitis Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">dHACM: MiMedx<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I)&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">MP 1032: MetrioPharm<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Tendinitis Key Companies<\/p>\n<p style=\"text-align: justify;\">Tendinitis Key Products<\/p>\n<p style=\"text-align: justify;\">Tendinitis- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Tendinitis- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Tendinitis- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Tendinitis Analyst Views<\/p>\n<p style=\"text-align: justify;\">Tendinitis Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: https:\/\/www.delveinsight.com\/sample-request\/tendinitis-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><br \/> DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=tendinitis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-seikagaku-corporation-metriopharm-mimedx-zhejiang-xingyue-biotechnology-co-ltd-r3-stem-cell-dobecure\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/tendinitis-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/tendinitis-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/tendinitis-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=tendinitis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-seikagaku-corporation-metriopharm-mimedx-zhejiang-xingyue-biotechnology-co-ltd-r3-stem-cell-dobecure\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tendinitis Pipeline Tendinitis is an inflammation of a tendon, a group of sturdy fibers that connects a muscle to the nearby bone. Another commonly used term for tendinitis is tendinopathy. Tendinitis is generally caused by injury, trauma, or overuse of &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/tendinitis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-seikagaku-corporation-metriopharm-mimedx-zhejiang-xingyue-biotechnology-co-ltd-r3-stem-cell-dobecure_542769.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-542769","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542769","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=542769"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542769\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=542769"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=542769"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=542769"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}